# PDGFRA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PDGFRA is a receptor tyrosine kinase crucial for mesenchymal cell development and tissue homeostasis, whose dysregulation through mutations, amplification, or autocrine signaling drives malignancies like GISTs and glioblastoma.
- Activating mutations, particularly D842V in exon 18, are a major cause of imatinib resistance in GISTs, necessitating targeted therapies like avapritinib.
- The FIP1L1-PDGFRA fusion oncogene, arising from a 4q12 deletion, confers exquisite sensitivity to low-dose imatinib in chronic eosinophilic leukemia and idiopathic hypereosinophilic syndrome.
- PDGFRA amplification, rather than point mutations, is the primary mechanism of its oncogenic activation in glioblastoma, often co-occurring with KIT and KDR amplification.
- Viral proteins (e.g., SV40 LT, HBV HBx) and bacterial factors (e.g., H. pylori CagA) can hijack PDGFRA signaling pathways to promote cell proliferation and oncogenesis.
- Specific tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, regorafenib, and the highly selective avapritinib are critical therapeutic agents, with drug efficacy dictated by the specific PDGFRA mutation profile.

---

## Executive Summary & Key Metadata

The Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) gene encodes a class III receptor tyrosine kinase (RTK) that is fundamental to mesenchymal cell biology, embryonic development, and adult tissue homeostasis. Its dysregulation—through activating mutations, genomic amplification, or autocrine ligand stimulation—is a defining feature of several malignancies, most notably gastrointestinal stromal tumors (GISTs), glioblastoma multiforme (GBM), and a spectrum of myeloid neoplasms. The protein product is a single-pass transmembrane receptor that transduces signals from PDGF-A, PDGF-B, PDGF-C, and PDGF-D ligands, activating a cascade of downstream pathways including RAS/MAPK, PI3K/AKT, and PLCγ. The clinical relevance of PDGFRA is underscored by the success of tyrosine kinase inhibitors (TKIs) such as imatinib, which target the ATP-binding pocket of the kinase domain, and by the emergence of highly specific next-generation inhibitors for resistance mutations.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | PDGFRA |
| **UniProt Accession** | P16234 |
| **Representative PDB ID** | True (e.g., 6JOL, 4LJ0) |
| **Chromosomal Locus** | 4q12 (GRCh38: chr4:54,229,293-54,298,245) |
| **Primary Molecular Function** | Receptor tyrosine kinase; signal transduction for cell proliferation, survival, migration, and differentiation |
| **Disease & Pathology Associations** | Gastrointestinal stromal tumor (GIST), glioblastoma, idiopathic hypereosinophilic syndrome (HES), systemic mastocytosis with eosinophilia, inflammatory fibroid polyp, and familial GIST syndromes |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

The PDGFRA gene is located on the long arm of chromosome 4 at cytogenetic band 4q12. This region is a known "kinase gene cluster," containing PDGFRA, KIT, and KDR (VEGFR2) within a span of approximately 500 kilobases. The proximity of these genes is not merely coincidental; they share a common ancestral gene duplication event and are co-regulated in certain cellular contexts. The genomic coordinates for PDGFRA (GRCh38/hg38 assembly) are chr4:54,229,293–54,298,245, spanning roughly 69 kilobases of genomic DNA. The gene is transcribed from the minus (reverse) strand.

The PDGFRA locus is characterized by a complex regulatory landscape. The core promoter region lacks a canonical TATA box but contains multiple GC-rich elements, including binding sites for the transcription factor Sp1 (Specificity Protein 1). These Sp1 sites are essential for basal transcription in mesenchymal progenitors. Upstream of the core promoter, several enhancer elements have been identified through chromatin immunoprecipitation sequencing (ChIP-seq) studies. These enhancers are marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (monomethylation of histone H3 lysine 4) in embryonic stem cells and neural crest derivatives. A critical distal enhancer, located approximately 100 kb upstream of the transcription start site (TSS), has been shown to drive expression in the developing limb bud and craniofacial mesenchyme.

The gene contains 23 exons, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 23. The intron-exon boundaries are highly conserved across mammals. Notably, exon 11 encodes the juxtamembrane (JM) domain, which is a mutational hotspot in GISTs. Exon 12 encodes the proximal part of the split kinase domain (TK1), while exon 14 encodes the kinase insert domain. Exons 18 and 19 encode the second part of the kinase domain (TK2) and the activation loop, respectively.

### 1.2 Promoter Architecture and Transcription Factor Binding

The 5' untranslated region (5' UTR) of PDGFRA is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs). These uORFs serve as translational brakes, allowing the cell to rapidly modulate PDGFRA protein levels in response to stress signals without altering transcription. The core promoter spans approximately 200 base pairs upstream of the TSS and is constitutively active in cells of mesenchymal origin.

Several transcription factors have been experimentally validated to bind the PDGFRA promoter and enhancers:

- **Sp1**: Binds GC-boxes in the proximal promoter; essential for basal expression.
- **ETS family (ETS1, FLI1)**: Bind to ETS motifs in the proximal promoter and enhancers; critical for endothelial and hematopoietic expression.
- **SOX10**: A master regulator of neural crest development; binds to a conserved enhancer in intron 1 and drives PDGFRA expression in melanocytes and enteric neural crest progenitors.
- **PAX3 and PAX7**: Paired-box transcription factors that bind upstream enhancers in myogenic progenitors.
- **WT1**: Wilms' tumor suppressor; represses PDGFRA transcription in podocytes, and its loss leads to overexpression in nephroblastoma.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of PDGFRA generates multiple transcript variants, although the functional significance of many remains incompletely characterized. The primary transcript encodes the canonical 1,089-amino acid receptor. However, several splice variants have been documented:

1. **Soluble PDGFRA (sPDGFRA)**: A splice variant that skips exon 14, leading to a frameshift and premature termination. This produces a truncated, secreted protein that lacks the transmembrane and kinase domains. sPDGFRA acts as a decoy receptor, sequestering PDGF ligands and modulating signaling. Elevated levels of sPDGFRA have been detected in the plasma of patients with systemic sclerosis and certain fibrotic diseases.

2. **PDGFRA-Δ8-9**: An in-frame deletion of exons 8 and 9, which removes part of the extracellular immunoglobulin (Ig)-like domain 4. This variant has been reported in a subset of GISTs and may alter ligand-binding specificity.

3. **PDGFRA-ΔJM**: A variant lacking exon 11 (the juxtamembrane domain) due to alternative splicing. This isoform exhibits constitutive kinase activity in vitro, suggesting that the JM domain normally exerts an autoinhibitory function. However, this splice isoform is rarely expressed at high levels in normal tissues, and its detection in tumors is often associated with genomic deletions rather than alternative splicing.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The PDGFRA protein (UniProt P16234) is a single-pass type I transmembrane glycoprotein of 1,089 amino acids. Its domain architecture, from N-terminus to C-terminus, is as follows:

- **Signal Peptide (aa 1–23)**: Cleaved during translocation to the endoplasmic reticulum.
- **Extracellular Domain (aa 24–524)**: Comprises five immunoglobulin (Ig)-like domains (D1–D5). These domains are responsible for ligand binding and receptor dimerization.
  - **D1 (aa 24–129)**: The membrane-distal domain; contains the primary ligand-binding interface.
  - **D2 (aa 130–222)**: Participates in ligand binding and provides specificity for PDGF-AA and PDGF-CC.
  - **D3 (aa 223–315)**: Structural domain; contributes to the ligand-binding pocket.
  - **D4 (aa 316–420)**: Contains the "dimerization arm" that mediates receptor-receptor contacts upon ligand binding.
  - **D5 (aa 421–524)**: Membrane-proximal domain; contains a juxtamembrane extracellular region that is flexible and may interact with the cell surface glycocalyx.
- **Transmembrane Helix (aa 525–547)**: A hydrophobic α-helix that anchors the receptor in the plasma membrane. Mutations in this region (e.g., V536D) have been identified in GISTs and result in constitutive dimerization.
- **Juxtamembrane Domain (aa 548–575)**: Intracellular region that adopts an autoinhibitory conformation in the inactive state. This domain is encoded by exon 11 and is the most frequent site of activating mutations in GISTs.
- **Kinase Domain 1 (TK1) (aa 576–680)**: The N-terminal lobe of the split kinase domain; contains the ATP-binding pocket (P-loop) and the conserved lysine residue (K627) that coordinates ATP.
- **Kinase Insert Domain (aa 681–760)**: A poorly conserved region that contains phosphorylation sites (e.g., Y720, Y731) that serve as docking sites for downstream signaling molecules such as PI3K and PLCγ.
- **Kinase Domain 2 (TK2) (aa 761–940)**: The C-terminal lobe of the kinase domain; contains the catalytic aspartate (D836) and the activation loop (A-loop) that must be phosphorylated for full catalytic activity.
- **C-Terminal Tail (aa 941–1089)**: Contains additional tyrosine phosphorylation sites (e.g., Y988, Y1018) and a PDZ-binding motif at the extreme C-terminus that mediates interactions with scaffolding proteins.

### 2.2 Structural Biology of the Inactive and Active States

Crystal structures of PDGFRA (and the highly homologous KIT receptor) have revealed the molecular basis of autoinhibition. In the inactive state, the juxtamembrane domain inserts into the kinase domain between TK1 and TK2, acting as a "molecular brake." Specifically, the JM domain forms a kinked helix that occupies the ATP-binding cleft and prevents the A-loop from adopting its active, extended conformation. This autoinhibited state is stabilized by hydrophobic interactions between the JM domain and the C-helix of TK1.

Ligand binding to the extracellular Ig-like domains induces receptor dimerization. The D1 and D3 domains of one receptor bind to one PDGF ligand dimer, while the D1 and D3 domains of the second receptor bind to the opposite face of the ligand dimer. This 2:2 (ligand:receptor) complex brings the two receptors into close proximity, allowing the intracellular kinase domains to trans-phosphorylate each other. The first phosphorylation event occurs on tyrosine residues in the JM domain (Y572, Y574), which disrupts the autoinhibitory interaction. Subsequent phosphorylation of the A-loop tyrosines (Y849, Y855) locks the kinase in an active, open conformation.

The active kinase domain adopts a bilobed structure typical of protein kinases. The N-lobe (TK1) contains a five-stranded β-sheet and the αC-helix, while the C-lobe (TK2) is predominantly α-helical. ATP binds in the cleft between the two lobes, with the adenine ring forming hydrogen bonds with the hinge region (residues E644–C646). The catalytic aspartate (D836) coordinates the magnesium ion required for phosphotransfer. The activation loop, when phosphorylated, moves away from the catalytic cleft, allowing substrate access.

### 2.3 Post-Translational Modifications

PDGFRA is heavily glycosylated, with N-linked glycosylation sites in the extracellular domain (e.g., N30, N51, N97, N116). Glycosylation is essential for proper folding and trafficking to the cell surface. The mature receptor has a molecular weight of approximately 170–180 kDa, with the core polypeptide contributing ~120 kDa.

Ubiquitination is a key regulatory mechanism. Upon ligand stimulation, the E3 ubiquitin ligase CBL (Casitas B-lineage Lymphoma) is recruited to phosphorylated tyrosine residues (particularly Y762) and ubiquitinates the receptor, marking it for endocytosis and lysosomal degradation. This negative feedback loop is critical for terminating signaling. Mutations that disrupt CBL binding (e.g., Y762F) lead to prolonged receptor signaling and have been implicated in tumorigenesis.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load PDGFRA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P16234)

The interactive visualizer allows users to explore the three-dimensional structure of the PDGFRA kinase domain in its active and inactive conformations. Key structural features to examine include the JM domain autoinhibitory latch, the ATP-binding pocket, the activation loop, and the positions of clinically relevant mutations (e.g., D842V, V561D, T674I). Users can toggle between the apo (inactive) and ligand-bound (active) states to visualize the conformational changes that occur upon activation.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand-Receptor Interactions

PDGFRA binds with high affinity to four of the five PDGF ligands: PDGF-A, PDGF-B, PDGF-C, and PDGF-D. The ligands are disulfide-linked homodimers (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD) or heterodimers (PDGF-AB). PDGFRA can form homodimers (PDGFRA/PDGFRA) or heterodimers with PDGFRB (PDGFRA/PDGFRB), depending on the ligand. PDGF-AA and PDGF-CC bind exclusively to PDGFRA homodimers, while PDGF-BB and PDGF-DD can bind both PDGFRA and PDGFRB. PDGF-AB binds PDGFRA/PDGFRB heterodimers with high affinity.

The binding affinity of PDGF-AA for PDGFRA is in the picomolar range (Kd ≈ 10 pM), making it one of the highest-affinity growth factor-receptor interactions known. The structural basis for this high affinity lies in the extensive hydrophobic and electrostatic contacts between the ligand and the D1 and D3 Ig-like domains.

### 3.2 Downstream Signaling Cascades

Upon ligand-induced dimerization and autophosphorylation, PDGFRA recruits a variety of Src Homology 2 (SH2) domain-containing proteins. The major signaling pathways activated are:

**RAS/MAPK Pathway**: The adaptor protein GRB2 binds to phosphorylated Y762 and recruits SOS, a guanine nucleotide exchange factor for RAS. Activated RAS triggers the RAF/MEK/ERK cascade, leading to phosphorylation of transcription factors such as ELK1 and MYC. This pathway promotes cell proliferation and is frequently hyperactivated in PDGFRA-mutant tumors.

**PI3K/AKT Pathway**: The p85 regulatory subunit of phosphoinositide 3-kinase (PI3K) binds to phosphorylated Y720 and Y731 in the kinase insert domain. PI3K generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which recruits AKT to the plasma membrane. AKT phosphorylates a wide array of substrates, including mTORC1, BAD, and FOXO transcription factors, promoting cell survival and metabolism. The tumor suppressor PTEN negatively regulates this pathway.

**PLCγ Pathway**: Phospholipase C gamma (PLCγ) binds to phosphorylated Y988 and Y1018 in the C-terminal tail. PLCγ hydrolyzes PIP2 to generate diacylglycerol (DAG) and inositol trisphosphate (IP3), leading to protein kinase C (PKC) activation and calcium release from the endoplasmic reticulum. This pathway regulates cell migration and cytoskeletal reorganization.

**JAK/STAT Pathway**: PDGFRA can also activate Janus kinases (JAKs) indirectly, leading to STAT transcription factor phosphorylation. STAT3 and STAT5 have been shown to be activated in PDGFRA-mutant GISTs and contribute to tumor growth.

**SRC Family Kinases**: SRC binds to phosphorylated Y572 and Y574 in the juxtamembrane domain. SRC activation leads to phosphorylation of focal adhesion kinase (FAK) and paxillin, promoting cell migration and invasion.

### 3.3 Regulatory Feedback Loops

PDGFRA signaling is tightly regulated by multiple negative feedback mechanisms:

1. **CBL-Mediated Degradation**: As mentioned, CBL ubiquitinates activated PDGFRA, targeting it for endocytosis and lysosomal degradation. This is the primary mechanism for terminating signaling.

2. **DUSP (Dual-Specificity Phosphatase) Induction**: ERK activation induces the transcription of DUSP1, DUSP4, and DUSP6, which dephosphorylate and inactivate ERK, creating a negative feedback loop.

3. **Sprouty Proteins**: SPRY1 and SPRY2 are transcriptionally induced by ERK signaling and act as inhibitors of the RAS/MAPK pathway by interfering with GRB2-SOS complex formation.

4. **MicroRNA Regulation**: Several microRNAs, including miR-34a and miR-221/222, target the PDGFRA 3' UTR and downregulate receptor expression. These miRNAs are frequently downregulated in GBM, contributing to PDGFRA overexpression.

### 3.4 Protein-Protein Interaction Networks

The PDGFRA interactome is extensive. Key interaction partners (validated by BioGRID and STRING) include:

- **CBL**: E3 ubiquitin ligase; negative regulator.
- **GRB2**: Adaptor protein; links to RAS/MAPK.
- **PIK3R1 (p85α)**: Regulatory subunit of PI3K.
- **PLCγ1**: Phospholipase; calcium signaling.
- **SRC**: Non-receptor tyrosine kinase.
- **SHC1**: Adaptor protein; alternative route to RAS activation.
- **NCK1/NCK2**: Adaptor proteins; link to actin cytoskeleton.
- **PTPN11 (SHP2)**: Protein tyrosine phosphatase; both positive and negative regulatory roles.
- **TENC1**: Tensin-like protein; links to integrin signaling.

```mermaid
sequenceDiagram
    participant L as "PDGF-AA Ligand"
    participant R as "PDGFRA Receptor"
    participant K as "Kinase Domain"
    participant G as "GRB2/SOS"
    participant M as "RAS/MAPK"
    participant P as "PI3K/AKT"
    participant C as "CBL"
    L->>R: Binds D1/D3 domains
    R->>R: Dimerization
    R->>K: Trans-autophosphorylation (Y572, Y574, Y720, Y762, Y849)
    K->>G: Recruits GRB2 via pY762
    G->>M: Activates RAS → RAF → MEK → ERK
    K->>P: Recruits p85 via pY720/pY731
    P->>P: PIP3 generation → AKT activation
    K->>C: Recruits CBL via pY762
    C->>R: Ubiquitination → Endocytosis → Degradation
    M->>M: Induces DUSP/Sprouty (negative feedback)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum in GISTs

PDGFRA mutations are found in approximately 5–8% of adult GISTs and are mutually exclusive with KIT mutations. The most common PDGFRA mutations are:

- **D842V (exon 18)**: This is the most frequent PDGFRA mutation, accounting for ~60% of PDGFRA-mutant GISTs. The substitution of valine for aspartate at position 842 in the activation loop locks the kinase in an active conformation by stabilizing the A-loop in its open state. D842V confers primary resistance to imatinib and most other TKIs, but is sensitive to avapritinib (BLU-285), a highly selective PDGFRA inhibitor.

- **V561D (exon 12)**: A missense mutation in the juxtamembrane domain that disrupts the autoinhibitory interaction, leading to constitutive kinase activity. V561D is sensitive to imatinib.

- **Deletions in exon 11**: In-frame deletions of the juxtamembrane domain (e.g., del 558–562) remove the autoinhibitory latch, causing constitutive activation. These mutations are imatinib-sensitive.

- **N659K (exon 14)**: A mutation in the kinase insert domain that is imatinib-sensitive but may confer resistance to some second-generation inhibitors.

- **T674I (exon 14)**: This mutation is the PDGFRA analog of the T315I mutation in BCR-ABL and confers resistance to imatinib and sunitinib.

### 4.2 PDGFRA in Glioblastoma

In GBM, PDGFRA is frequently amplified (in ~10–15% of cases) and overexpressed. Unlike GISTs, activating point mutations are rare in GBM. Instead, the predominant mechanism of activation is genomic amplification and autocrine/paracrine ligand stimulation. PDGFRA amplification is particularly common in the "proneural" molecular subtype of GBM, which is associated with younger patient age and better prognosis. The amplification often involves a tandem duplication of the 4q12 locus, leading to co-amplification of KIT and KDR.

### 4.3 PDGFRA in Myeloid Neoplasms

FIP1L1-PDGFRA is a fusion oncogene resulting from a cryptic deletion on chromosome 4q12 that fuses the 5' portion of FIP1L1 to the 3' portion of PDGFRA. This fusion is found in a subset of patients with chronic eosinophilic leukemia (CEL) and idiopathic hypereosinophilic syndrome (HES). The fusion protein lacks the extracellular domain of PDGFRA but retains the kinase domain, which is constitutively active due to the loss of the autoinhibitory JM domain. FIP1L1-PDGFRA is exquisitely sensitive to imatinib, and imatinib is the first-line therapy for this condition.

Other rare PDGFRA fusions include ETV6-PDGFRA and CDK5RAP2-PDGFRA, which have been reported in atypical chronic myeloid leukemia (aCML) and B-cell acute lymphoblastic leukemia (B-ALL).

### 4.4 Other Diseases

- **Inflammatory Fibroid Polyp (IFP)**: Benign gastrointestinal tumors that harbor activating PDGFRA mutations, most commonly in exon 12 or exon 18. These mutations are identical to those found in GISTs but do not progress to malignancy.

- **Familial GIST Syndrome**: Germline mutations in PDGFRA (e.g., V561D) cause a hereditary predisposition to GISTs, often associated with other features such as lipomas and skin hyperpigmentation.

- **Atherosclerosis**: PDGFRA signaling in vascular smooth muscle cells contributes to neointimal hyperplasia. Polymorphisms in the PDGFRA gene have been associated with increased risk of coronary artery disease.

### 4.5 ClinVar Classification

ClinVar lists numerous PDGFRA variants. The classification of key variants is as follows:

| Variant | ClinVar Classification | Disease Association |
|---|---|---|
| D842V | Pathogenic | GIST, imatinib-resistant |
| V561D | Pathogenic | GIST, familial GIST |
| N659K | Pathogenic | GIST |
| T674I | Pathogenic | GIST, imatinib-resistant |
| R748C | Likely pathogenic | GIST |
| Y849C | Pathogenic | GIST |
| P577S | Uncertain significance | — |
| G664R | Uncertain significance | — |

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of PDGFRA

Several viruses have evolved mechanisms to hijack PDGFRA signaling to promote viral replication or oncogenesis.

**Simian Virus 40 (SV40)**: The SV40 large T antigen (LT) has been shown to upregulate PDGFRA expression in infected cells. LT binds to the PDGFRA promoter and activates transcription, leading to sustained mitogenic signaling that creates a favorable environment for viral DNA replication. This interaction is particularly relevant in the context of SV40-induced mesotheliomas in animal models.

**Hepatitis B Virus (HBV)**: The HBV X protein (HBx) has been reported to transactivate the PDGFRA promoter in hepatocytes. This upregulation of PDGFRA contributes to the epithelial-mesenchymal transition (EMT) observed in HBV-associated hepatocellular carcinoma (HCC).

**Kaposi's Sarcoma-Associated Herpesvirus (KSHV)**: KSHV encodes a viral G protein-coupled receptor (vGPCR) that can transactivate PDGFRA through paracrine mechanisms. KSHV-infected endothelial cells secrete PDGF-AA, which activates PDGFRA on neighboring cells, promoting angiogenesis and spindle cell formation characteristic of Kaposi's sarcoma.

### 5.2 Bacterial Interactions

**Helicobacter pylori**: Chronic infection with H. pylori is a risk factor for gastric cancer. The bacterial virulence factor CagA has been shown to activate PDGFRA signaling in gastric epithelial cells. CagA is translocated into host cells via a type IV secretion system and can bind to and activate SHP2, which in turn potentiates PDGFRA downstream signaling. This interaction promotes cell proliferation and inhibits apoptosis, contributing to gastric carcinogenesis.

**Mycobacterium tuberculosis**: In macrophages infected with M. tuberculosis, PDGFRA expression is upregulated. This upregulation is thought to promote granuloma formation by recruiting fibroblasts and promoting fibrosis. The bacterial cell wall component lipoarabinomannan (LAM) has been shown to induce PDGFRA expression through a TLR2-dependent mechanism.

### 5.3 Parasitic Interactions

**Schistosoma mansoni**: Schistosomiasis is associated with hepatic fibrosis. Soluble egg antigens (SEA) from S. mansoni have been shown to upregulate PDGFRA expression in hepatic stellate cells, promoting their activation and the subsequent deposition of extracellular matrix. This contributes to the development of portal hypertension and its complications.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Tyrosine Kinase Inhibitors

PDGFRA is a validated drug target, and several TKIs with activity against PDGFRA are FDA-approved:

**Imatinib (Gleevec)**: A first-generation TKI that inhibits BCR-ABL, KIT, and PDGFRA. Imatinib is approved for the treatment of KIT-positive GISTs and FIP1L1-PDGFRA-positive CEL. It binds to the inactive conformation of the kinase domain, occupying the ATP-binding pocket. The D842V mutation disrupts the inactive conformation, preventing imatinib binding and conferring resistance.

**Sunitinib (Sutent)**: A multi-targeted TKI that inhibits PDGFRA, PDGFRB, VEGFR1-3, KIT, and FLT3. Sunitinib is approved as second-line therapy for GISTs resistant to imatinib. It binds to the active conformation of the kinase domain and can overcome some imatinib-resistant mutations, but not D842V.

**Regorafenib (Stivarga)**: A multi-kinase inhibitor targeting PDGFRA, PDGFRB, VEGFR1-3, KIT, RET, and RAF. Approved as third-line therapy for GISTs.

**Avapritinib (Ayvakit)**: A highly selective inhibitor of PDGFRA and KIT. Avapritinib is uniquely effective against the D842V mutation and is approved for the treatment of GISTs harboring PDGFRA exon 18 mutations, including D842V. It binds to the active conformation and forms a covalent-like interaction with the kinase domain, providing sustained inhibition.

**Sorafenib (Nexavar)**: A multi-kinase inhibitor with activity against PDGFRA, VEGFR, RAF, and KIT. Approved for hepatocellular carcinoma and renal cell carcinoma.

### 6.2 Investigational Agents

**Crenolanib**: A potent inhibitor of PDGFRA and PDGFRB that is in clinical trials for GISTs with D842V mutations. Unlike imatinib, crenolanib binds to the active conformation and can inhibit D842V. However, clinical responses have been variable, and resistance can emerge through secondary mutations.

**Olverembatinib (HQP1351)**: A third-generation TKI that is being evaluated for its activity against PDGFRA-mutant GISTs, including those with D842V.

**BLU-263 (Avapritinib analog)**: A next-generation inhibitor with improved selectivity and reduced off-target effects.

### 6.3 Monoclonal Antibodies

**Olaratumab (Lartruvo)**: A fully human monoclonal antibody that binds to PDGFRA and blocks ligand binding. It was initially approved for soft tissue sarcoma in combination with doxorubicin, but the approval was withdrawn in 2019 after a confirmatory trial failed to show improved overall survival.

**IMC-3G3**: A fully human anti-PDGFRA antibody that has been evaluated in clinical trials for GBM. It blocks ligand binding and induces receptor internalization.

### 6.4 Pharmacogenomic Considerations

The efficacy of PDGFRA-targeted therapy is highly dependent on the specific mutation present. Key pharmacogenomic principles:

- **D842V**: Resistant to imatinib, sunitinib, and regorafenib; sensitive to avapritinib and crenolanib.
- **V561D**: Sensitive to imatinib.
- **T674I**: Resistant to imatinib; sensitivity to avapritinib is being evaluated.
- **FIP1L1-PDGFRA**: Highly sensitive to imatinib at low doses (100 mg/day).

Therapeutic drug monitoring (TDM) of imatinib is recommended in GIST patients, as trough levels below 1,100 ng/mL are associated with poorer outcomes. Genetic polymorphisms in drug-metabolizing enzymes (CYP3A4, CYP3A5) and transporters (ABCG2, ABCB1) can influence imatinib pharmacokinetics and should be considered in dose adjustment.

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | URL |
|---|---|---|
| NCBI Gene | 5156 | https://www.ncbi.nlm.nih.gov/gene/5156 |
| Ensembl | ENSG00000134853 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134853 |
| UniProt | P16234 | https://www.uniprot.org/uniprotkb/P16234 |
| RCSB PDB | 6JOL (kinase domain, active) | https://www.rcsb.org/structure/6JOL |
| RCSB PDB | 4LJ0 (kinase domain, inactive) | https://www.rcsb.org/structure/4LJ0 |
| OMIM | 173490 | https://www.omim.org/entry/173490 |
| ClinVar | PDGFRA | https://www.ncbi.nlm.nih.gov/clinvar/?term=PDGFRA |
| COSMIC | PDGFRA | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDGFRA |
| STRING | P16234 | https://string-db.org/network/P16234 |
| BioGRID | 112358 | https://thebiogrid.org/112358 |
| Gene Ontology (GO) | GO:0004714 (transmembrane receptor protein tyrosine kinase activity) | https://www.ebi.ac.uk/QuickGO/term/GO:0004714 |
| Gene Ontology (GO) | GO:0048008 (platelet-derived growth factor receptor signaling pathway) | https://www.ebi.ac.uk/QuickGO/term/GO:0048008 |
| Gene Ontology (GO) | GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/term/GO:0005886 |
| Reactome | R-HSA-186797 (PDGF signaling) | https://reactome.org/content/detail/R-HSA-186797 |
| KEGG | hsa05166 (Human T-cell leukemia virus 1 infection) | https://www.genome.jp/kegg-bin/show_pathway?hsa05166 |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science*. 2003;299(5607):708-710. doi:10.1126/science.1079666.
2. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. *Gastroenterology*. 2003;125(3):660-667. doi:10.1016/s0016-5085(03)01046-1.
3. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med*. 2003;348(13):1201-1214. doi:10.1056/NEJMoa025217.
4. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*. 2010;17(1):98-110. doi:10.1016/j.ccr.2009.12.020.
5. Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. *Sci Transl Med*. 2017;9(414):eaao1690. doi:10.1126/scitranslmed.aao1690.
6. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol*. 2005;23(23):5357-5364. doi:10.1200/JCO.2005.14.068.
7. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. *Histopathology*. 2008;53(3):245-266. doi:10.1111/j.1365-2559.2008.02977.x.
8. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. *Genes Dev*. 2008;22(10):1276-1312. doi:10.1101/gad.1653708.
9. Heldin CH, Lennartsson J, Westermark B. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. *J Intern Med*. 2018;283(1):16-44. doi:10.1111/joim.12690.
10. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med*. 2002;347(7):472-480. doi:10.1056/NEJMoa020461.
11. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2013;381(9863):295-302. doi:10.1016/S0140-6736(12)61857-1.
12. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label, phase 1b and randomised phase 2 trial. *Lancet*. 2016;388(10043):488-497. doi:10.1016/S0140-6736(16)30587-6.
13. Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. *Lancet Oncol*. 2020;21(7):935-946. doi:10.1016/S1470-2045(20)30269-2.
14. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. *J Biol Chem*. 2004;279(30):31655-31663. doi:10.1074/jbc.M403319200.
15. Liang